Golden
Eligo Bioscience

Eligo Bioscience

Biotherapeautics company founded in 2014 and based in Paris that uses proprietary methods in synthetic biology, protein and genome engineering to produce Eligobiotics, products which intervene with the microbiome as diagnostics, antimicrobials and modulators of host-microbiome interactions.

All edits

Edits on 18 Sep 2019
Golden AI
Golden AI edited on 18 Sep 2019 5:52 am
Edits made to:
Infobox (+1 properties)
Edits on 11 Apr 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr 2019 7:12 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 3 Apr 2019
Dawson Sewell
Dawson Sewell edited on 3 Apr 2019 8:32 pm
Edits made to:
Infobox (+1 properties)
Dawson Sewell
Dawson Sewell edited on 3 Apr 2019 8:31 pm
Edits made to:
Infobox (+5 properties)
Article (+612/-286 characters)

Article

In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”. Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.



Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.

Funding

Seed

On July 9, 2015 Eligo Bioscience completed their seed funding round with €2.6M from Seventure Partners (lead investor) and Worldwide Innovation Challenge. 

Series A

On September 26, 2017 Eligo Bioscience completed their series A funding round with $20million in funding from Seventure Partners and Khosla Ventures. 

Infobox

Location
Date incorporated
2014
Edits on 14 Feb 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 14 Feb 2019 6:01 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 6 Feb 2019
Meredith Hanel
Meredith Hanel edited on 6 Feb 2019 11:37 pm
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 15 Jan 2019
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 15 Jan 2019 11:49 pm
Edits made to:
Article (+3/-3 characters)

Article

In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”. Their antimicrobials do not edit bacterial DNADNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.

Carla Faraguna
Carla Faraguna edited on 15 Jan 2019 7:33 pm
Edits made to:
Infobox (+2 properties)
Topic thumbnail

Eligo Biosciences Eligo Bioscience

Biotherapeautics company founded in 2014 and based in Paris that uses proprietary methods in synthetic biology, protein and genome engineering to produce Eligobiotics, products which intervene with the microbiome as diagnostics, antimicrobials and modulators of host-microbiome interactions.

Infobox

Country
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:13 pm
Edits made to:
Article (+22/-22 characters)

Article

Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller UniversityRockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in Paris and now resides at the Paris Biotech Santé at Cochin Hospital.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:11 pm
Edits made to:
Article (+5/-5 characters)

Article

Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in ParisParis and now resides at the Paris Biotech Santé at Cochin Hospital.

Edits on 14 Jan 2019
Meredith Hanel
Meredith Hanel edited on 14 Jan 2019 9:35 pm
Edits made to:
Categories (+1 topics)
Meredith Hanel
Meredith Hanel edited on 14 Jan 2019 8:24 pm
Edits made to:
Description (+291/-85 characters)
Article (+1017 characters)
People (+4 rows) (+8 cells) (+123 characters)
Categories (+1 topics)
Topic thumbnail

Eligo Bioscience

Biotherapeautics company for bacteria-associated diseases and microbiome engineering.

Biotherapeautics company founded in 2014 and based in Paris that uses proprietary methods in synthetic biology, protein and genome engineering to produce Eligobiotics, products which intervene with the microbiome as diagnostics, antimicrobials and modulators of host-microbiome interactions.

Article

Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in Paris and now resides at the Paris Biotech Santé at Cochin Hospital.



Eligo Bioscience develops Eligobiotics, which are nano-delivery vehicles that are based on non-replicative phage particles that are engineered and programmed to package synthetic genetic circuits.

...

In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”. Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.

People

Name
Role
Related Golden topics

Dr. David Bikard

Co-Founder



Dr. Xavier Duportet

Co-Founder



Prof. Luciano Marraffini

Co-Founder



Prof. Timothy Lu, MD-PhD

Co-Founder



Categories

Edits on 14 Nov 2018
Melanie Manipula"Approved suggestion from source: http://ELIGO-BIOSCIENCE.COM"
Melanie Manipula approved a suggestion from Golden's AI on 14 Nov 2018 11:29 pm
Edits made to:
Infobox (+1 properties)
Melanie Manipula"Approved suggestion from source: http://ELIGO-BIOSCIENCE.COM"
Melanie Manipula approved a suggestion from Golden's AI on 14 Nov 2018 8:12 pm
Edits made to:
Infobox (+1 properties)
Edits on 9 Nov 2018
Jude Gomila"Approved suggestion from source: http://ELIGO-BIOSCIENCE.COM"
Jude Gomila approved a suggestion from Golden's AI on 9 Nov 2018 11:46 pm
Edits made to:
Infobox (+1 properties)
Edits on 16 Aug 2018
Carla Faraguna
Carla Faraguna edited on 16 Aug 2018 8:42 pm
Edits made to:
Infobox (+1 properties)

Infobox

Location
Edits on 15 Aug 2018
Carla Faraguna
Carla Faraguna edited on 15 Aug 2018 11:53 pm
Edits made to:
Infobox (+1 properties)
Description (+85 characters)
Categories (+1 topics)
Topic thumbnail

Eligo Bioscience

Biotherapeautics company for bacteria-associated diseases and microbiome engineering.

Infobox

Categories

Edits on 21 Apr 2018
Melanie Manipula
Melanie Manipula edited on 21 Apr 2018 12:02 am
Edits made to:
Topic thumbnail

Eligo Bioscience

Biotherapeautics company founded in 2014 and based in Paris that uses proprietary methods in synthetic biology, protein and genome engineering to produce Eligobiotics, products which intervene with the microbiome as diagnostics, antimicrobials and modulators of host-microbiome interactions.

Melanie Manipula"Initial topic creation"
Melanie Manipula created this topic on 20 Apr 2018 11:48 pm
Edits made to:
Description
Academic papers
People
Further reading
Documentaries, videos and podcasts
Companies
Products
Topic thumbnail

 Eligo Biosciences

Biotherapeautics company founded in 2014 and based in Paris that uses proprietary methods in synthetic biology, protein and genome engineering to produce Eligobiotics, products which intervene with the microbiome as diagnostics, antimicrobials and modulators of host-microbiome interactions.

No more activity to show.